1-8 of 8
idelalisib
Close
Sort by
Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Clinical Trials & Observations
Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2438–2446.
https://doi.org/10.1182/bloodadvances.2020003895
Published: 2021
Includes: Supplemental data
Journal Articles

PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax

Neus Serrat, Martina Guerrero-Hernández, Alba Matas-Céspedes, Anella Yahiaoui, Juan G. Valero, Ferran Nadeu, Guillem Clot, Miriam Di Re, Marc Corbera-Bellalta, Laura Magnano, Alfredo Rivas-Delgado, Anna Enjuanes, Silvia Beà, Maria C. Cid, Elías Campo, Joan Montero, Daniel J. Hodson, Armando López-Guillermo, Dolors Colomer, Stacey Tannheimer, Patricia Pérez-Galán
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4217–4231.
https://doi.org/10.1182/bloodadvances.2020001584
Published: 2020
Includes: Supplemental data
Journal Articles

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

Kamira Maharaj, John J. Powers, Alex Achille, Melanie Mediavilla-Varela, Wael Gamal, Karen L. Burger, Renee Fonseca, Kun Jiang, Hari P. Miskin, Dave Maryanski, Andrii Monastyrskyi, Derek R. Duckett, William R. Roush, John L. Cleveland, Eva Sahakian, Javier Pinilla-Ibarz
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3072–3084.
https://doi.org/10.1182/bloodadvances.2020001800
Published: 2020
Includes: Supplemental data
Journal Articles

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez, Catherine J. Wu
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3759–3769.
https://doi.org/10.1182/bloodadvances.2019000367
Published: 2019
Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1167–1174.
https://doi.org/10.1182/bloodadvances.2018030221
Published: 2019
Includes: Supplemental data
Journal Articles

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists

Christopher T. Petersen, Mojibade Hassan, Anna B. Morris, Jasmin Jeffery, Kunhee Lee, Neera Jagirdar, Ashley D. Staton, Sunil S. Raikar, Harold T. Spencer, Todd Sulchek, Christopher R. Flowers, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2018) 2 (3): 210–223.
https://doi.org/10.1182/bloodadvances.2017011254
Published: 2018
Includes: Supplemental data
Journal Articles

Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia

Kamira Maharaj, Eva Sahakian, Javier Pinilla-Ibarz
Journal: Blood Advances
Blood Adv (2017) 1 (21): 1867–1875.
https://doi.org/10.1182/bloodadvances.2017006809
Published: 2017
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data